Screening tools and methods for adverse events in head and neck cancer

Screening tools and methods to identify patients with head and neck cancer at risk for adverse events. A prospective study - Screening tools and methods to identify patients with head and neck cancer at risk for adverse events. A prospective study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON58482

Enrollment

256

Registered

2026-01-29

Start date

2026-05-21

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mucosal head and neck squamous cell carcinoma head and neck cancer

Interventions

Not applicable.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Primary mucosal squamous cell carcinoma of the:Oral cavity;Pharynx;Larynx;Unknown primary;-      A diagnostic CT-scan as part of diagnostic work-up;-      Treated with curative intent;-      Age =18 years;-      Written informed consent.

Exclusion criteria

Exclusion criteria: Residual or recurrent malignancy;Disability that could interfere with questionnaire fulfillment.

Design outcomes

Primary

Measure	Time frame
Adverse events. Complications will be measured within 30 days after surgery using the Clavien-Dindo classification. Toxicity will be evaluated using the Common Terminology Criteria for Adverse Events, version 4.0, 6 and 12 weeks after the start of (chemo)radiotherapy.	—

Secondary

Measure	Time frame
Length of hospital stay, number of readmissions, patient-reported quality of life (i.e., EORTC H&N35, EORTC C30, EQ-5D-5L questionnaires), recurrence, (disease-specific and overall) survival.	—

Countries

Netherlands

Contacts

Public ContactI. Wegner

Universitair Medisch Centrum Groningen

i.wegner@umcg.nl050 361 2550

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 29, 2026